Invasive Pneumococcal Disease in Healthy Adults: Increase of Empyema Associated with the Clonal-Type Sweden1-ST306

Imma Grau1, Carmen Ardanuy2, Laura Calatayud2, Dora Rolo2, Arnau Domenech2, Josefina Liñares2, Roman Pallares1*

1 Infectious Disease Department, Hospital Bellvitge, Idibell, Ciberes, University of Barcelona, Barcelona, Spain, 2 Microbiology Department, Hospital Bellvitge, Idibell, Ciberes, University of Barcelona, Barcelona, Spain

Abstract

**Background:** Adult invasive pneumococcal disease (IPD) occurs mainly in the elderly and patients with co-morbidities. Little is known about the clinical characteristics, serotypes and genotypes causing IPD in healthy adults.

**Methods:** We studied 745 culture-proven cases of IPD in adult patients aged 18–64 years (1996–2010). Patients were included in two groups: 1.) adults with co-morbidities, and 2.) healthy adults, who had no prior or coincident diagnosis of a chronic or immunosuppressive underlying disease. Microbiological studies included pneumococcal serotyping and genotyping.

**Results:** Of 745 IPD episodes, 525 (70%) occurred in patients with co-morbidities and 220 (30%) in healthy adults. The healthy adults with IPD were often smokers (56%) or alcohol abusers (18%). As compared to patients with co-morbidities, the healthy adults had (P<0.05): a younger age (43.5±13.1 vs. 48.7±11.3 years); higher proportions of women (45% vs. 24%); pneumonia with empyema (15% vs. 7%) and infection with non-PCV7 serotypes including serotypes 1 (25% vs. 5%), 7F (13% vs. 4%), and 5 (7% vs. 2%); and lower mortality (5% vs. 20%). Empyema was more frequently caused by serotype 1. No death occurred among 79 patients with serotype 1 IPD. There was an emergence of virulent clonal-types Sweden1-ST306 and Netherlands7F-ST191. The vaccine serotype coverage with the PCV13 was higher in healthy adults than in patients with co-morbidities: 82% and 56%, respectively, P<0.001.

**Conclusion:** In this clinical study, one-third of adults with IPD had no underlying chronic or immunosuppressive diseases (healthy adults). They were often smokers and alcohol abusers, and frequently presents with pneumonia and empyema caused by virulent clones of non-PCV7 serotypes such as the Sweden1-ST306. Thus, implementing tobacco and alcohol abuse-cessation measures and a proper pneumococcal vaccination, such as PCV13 policy, in active smokers and alcohol abusers may diminish the burden of IPD in adults.

Citation: Grau I, Ardanuy C, Calatayud L, Rolo D, Domenech A, et al. (2012) Invasive Pneumococcal Disease in Healthy Adults: Increase of Empyema Associated with the Clonal-Type Sweden1-ST306. PLoS ONE 7(8): e42595. doi:10.1371/journal.pone.0042595

**Competing Interests:** C. Ardanuy and J. Liñares have received funding unrelated to the current paper from Pfizer (for traveling to international meetings). All other authors declare no conflicts of interest. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: rpallares@ub.edu

Introduction

*Streptococcus pneumoniae* remains a major cause of morbidity and mortality worldwide. The pneumococcus, with more than 93 serotypes, usually colonizes the nasopharynx of young children, and more infrequently of adults, and occasionally can invade the lungs, bloodstream or brain causing severe infections [1–7].

Invasive pneumococcal disease (IPD) occurs mainly in young children and older adults (≥65 years) as well as in patients with co-morbidities (e.g., chronic lung disease, cardiovascular disease, cirrhosis, malignancies, HIV, asplenia) [5,6]. Although several case reports exist, little is known about the characteristics of IPD in healthy adults [6]. Some reports have also shown that young people who are smokers or alcohol abusers may be at higher risk of IPD [5,8].

The prevention of adult IPD has been based on the pneumococcal polysaccharide vaccine 23-valent (PPV23), which is recommended for the elderly and patients with co-morbidities [9]. However, its immunologic response and effectiveness may not be optimal in some populations, particularly in immunocompromised patients [10]. The 7-valent pneumococcal conjugate vaccine (PCV7), which usually produces a better immunologic response and may reduce acquisition of nasopharyngeal carriage, was introduced in the year 2000 for children in the USA [11] and it...
was followed by a decline in IPD caused by vaccine serotypes in children as well as in adults - through an indirect effect (herd protection) - [11,12]. The recent introduction of the PCV10 and PCV13 for children and currently for adults may change significantly the IPD epidemiology. However, the consequences of the “replacement phenomenon”, -that means the emergence of serotypes not contained in the conjugate vaccines- [13,14], are unknown.

Thus, it is important to know the serotypes causing IPD, including in healthy adults, in order to look for new target populations for implementing future vaccination strategies.

The objectives of our study were to analyze the clinical presentation, serotypes and clonal-type distribution, and mortality of IPD in healthy adults (aged 18–64 years).

Methods

We have collected data on all patients with IPD at our institution (Hospital Bellvitge, University of Barcelona) over the past three decades. A detailed description of the methodology was reported elsewhere [15–17].

For the present report, we studied all IPD episodes seen during the last 15 years (1/1996–12/2010) in adults aged 18–64 years. Patients were included in two groups: “healthy adults” and “patients with co-morbidities”.

Definitions

Culture-proven IPD was defined according to the clinical findings and the isolation of Streptococcus pneumoniae from a normally sterile body fluid such as blood, pleural fluid, cerebrospinal fluid (CSF), peritoneal fluid or joint fluid. Pneumococcal pneumonia was diagnosed in patients with signs or symptoms of an acute lower respiratory tract infection together with a new pulmonary infiltrate on chest radiograph. For the diagnosis of empyema, isolation of S. pneumoniae from the pleural fluid was required. Other origins of IPD (e.g., meningitis, peritonitis, arthritis) were diagnosed based on standard criteria.

Alcohol abuse was considered when the patient reported a daily alcohol intake of 80 gr. or 60 gr. for men and women, respectively, at least during the previous year. Current smoking was considered when the patient has been smoking at least ten cigarettes per day during the last year. It should be in mind that self reporting of alcohol and smoking habits is notoriously unreliable, and tend to underestimate consumption.

Special care was taken in assessing smokers and alcohol abusers to rule out associated co-morbidities. Prior antibiotic therapy was defined as the intake of any antibiotic for more than 48 hours during the previous 3 months.

We considered patients to be “healthy adults” when they had no prior or coincident diagnosis of a chronic or immunosuppressive underlying disease. Otherwise, “patients with co-morbidities” were those who had a confirmed diagnosis of one or more of the following: chronic pulmonary diseases (e.g., chronic obstructive pulmonary disease [COPD], emphysema, bronchiectasis, asthma, interstitial lung disease); cardiovascular diseases, chronic liver disease, diabetes, malignant disease, HIV infection, chronic rheumatic diseases or vasculitis, end stage chronic renal failure, cerebrovascular or degenerative brain diseases, asplenia, transplant recipients (bone marrow and solid-organ transplants), and long-term use of corticosteroids or other immunosuppressive therapies.

The diagnosis of septic shock was based on a systolic blood pressure below 90 mm Hg and peripheral hypoperfusion together with clinical and/or bacteriological evidence of uncontrolled infection. Antibiotic therapy was prescribed according to the hospital guidelines being the most frequent schedules for pneumonia: ceftriaxone, levofloxacin or macrolides, alone or in combination; and for meningitis: cefotaxime with or without vancomycin. Mortality was recorded when the patient died within 30 days of diagnosis.

Ethical statement. This study and publication of the results were approved by the “Institutional Review Board - Comite Étic d’Investigació Clinica del Hospital Universitari de Bellvitge”, and the Institutional Review Board specifically waived the need for consent because the study was retrospective and the source of data was anonymized.

Microbiological methods

Streptococcus pneumoniae strains were identified by conventional methods (opochin susceptibility and bile solubility). Pneumococci were serotyped by dot-blot assay or Quellung reaction at the Spanish Reference Laboratory, Majadahonda, Madrid, Spain.

We evaluated the vaccine serotype coverage of PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), PCV10 (additional 1, 5, 7F) and PCV13 (additional 3, 6A, 19A). In Spain, pneumococcal conjugate vaccines for children were introduced as follows: PCV7 in June 2001, PCV10 in May 2009 and PCV13 in June 2010.

Antimicrobial susceptibility to penicillin, cefotaxime, ceftriaxone, erythromycin, tetracycline, ciprofloxacin and co-trimoxazole were tested by microdilution method (Sensititre) following the Clinical Laboratory Standard Institute (CLSI) methods [18]. S. pneumoniae ATCC 6303 and S. pneumoniae ATCC 49619 were used as control strains. Antimicrobial resistances were determined according to the CLSI criteria [19].

Pulsed-field-gel-electrophoresis (PFGE) was performed to all available isolates. Genomic DNA embedded in agarose plugs was restricted with Smal (New England BioLabs) and fragments were separated by PFGE in a CHEF-DR3II apparatus (Bio-Rad). Multilocus sequence typing (MLST) was carried out as described previously [20] on selected strains that were representative isolates of PFGE clusters shared by three or more isolates. The allelic number and sequence types (ST) were assigned using the pneumococcal MLST web site http://spneumoniae.mlst.net/, which is located at Imperial College London and is funded by the Wellcome Trust. When an unusual association between serotype and sequence type was found, the serotype was confirmed by PCR, using previously described methodology (http://www. cdc.gov/ncidod/biotech/strep/pcr.htm), and MLST was repeated.

Statistical analysis

Statistical analysis was carried out with the PASW-18. We used Chi-square test or Fisher’s exact test for categorical variables (two-by-k contingency tables) and Student t test for continuous variables. Analyses were adjusted by means of multiple logistic regression models in order to determine those variables independently associated with healthy adults (compared to patients with co-morbidities). All P values were two-tailed and P<0.05 were considered statistically significant. To calculate the incidence rates we used as a denominator the number of persons, by age group per year, in the public database of the Web “Official Statistics in Catalonia” [21].

Results

Between 1/1996 and 12/2010, we studied 1414 IPD episodes in adult patients, in whom S.pneumoniae was isolated from one or more
sterile site: blood 1320, pleural fluid 128, CSF 107, abdominal fluid 68, and joint fluid 2.

Out of 1414 IPD episodes, 745 (53%) occurred in adults (aged 18–64 years) and 669 (47%) in elderly (≥65 years). Out of 745 IPD episodes in adults, 525 (70%) occurred in patients with co-morbidities and 220 (30%) in healthy adults. The co-morbidities diagnosed in our patients are shown at the foot of Table 1.

The incidence rates of IPD among adults (aged 18–64 years) in three periods (1996–2000 vs. 2001–2005 vs. 2006–2010) and according to PCV7 serotypes/non-PCV7 serotypes were: 3.5/5.0 vs. 2.9/6.8 vs. 2.5/9.2 episodes/100,000 (P<0.001) respectively.

Also, over the study period the proportion of IPD episodes in healthy adults increased: 18% (35/193) vs. 32% (78/245) vs. 35% (107/307), P<0.001.

There was an increase in non-PCV7 serotypes (periods: 1996–2000 vs. 2001–2005 vs. 2006–2010) among healthy adults: 66% (23/35) vs. 82% (64/78) vs. 86% (89/103), P = 0.02; and among patients with comorbidities: 57% (89/156) vs. 64% (106/165) vs. 75% (144/192), P = 0.002.

### Characteristics of healthy adults

As shown in Table 1, compared to patients with co-morbidities, the healthy adults had: younger age and higher proportion of women; more frequently pneumonia with empyema; and lower proportions of alcohol abusers, prior antibiotics, shock and mortality. The healthy adults also had lower antibiotic resistance rates.

Of note, the healthy adults with IPD were often smokers (56%) or alcohol abusers (18%), and when stratified by gender and age group (18–49 and 50–64 years) these percentages were: smokers (men, 73% and 48%; women, 39% and 20%); and alcohol abusers (men, 25% and 38%; women, 4% and 4%), Figure 1.

In the subgroup of 549 patients with pneumonia, healthy adults (compared to patients with co-morbidities) had: higher proportion of empyema 18% (33/182) vs.10% (36/367), P = 0.006; and lower proportions of multilobar pneumonia 23% (42/182) vs. 34% (123/367), P = 0.011, and respiratory failure 34% (61/182) vs. 52% (192/367), P<0.001.

Healthy adults (compared to patients with co-morbidities) had higher proportions of serotypes 1,7F and 5, and lower proportions of serotype 19F, 23F and others (Table 2). The distribution of serotypes in more recent years (period 2006–2010) is shown in

### Table 1. Characteristics of 745 invasive pneumococcal disease episodes in adults (aged 18–64 years): A comparison between patients with co-morbidities and healthy adults.

|                          | Healthy N = 220 | Co-morbidities* N = 525 | P Value   |
|--------------------------|-----------------|-------------------------|-----------|
| Age, mean+/−SD, years    |                 |                         |           |
| 18–49 yrs                | 43.53 (+/− 13.1)| 48.78 (+/−11.3)         | <0.001    |
| 50–64 yrs                | 86 (39)         | 268 (51)                |           |
| Sex                      |                 |                         |           |
| Female                   | 99 (45)         | 124 (24)                | <0.001    |
| Male                     | 121 (55)        | 401 (76)                |           |
| Alcohol abuse            | 39 (18)         | 130 (25)                | 0.030     |
| Current smoking          | 123 (56)        | 304 (58)                | 0.530     |
| Prior antibiotic therapy | 18 (8)          | 182 (35)                | <0.001    |
| Clinical syndromes       |                 |                         |           |
| Pneumonia with empyema   | 33 (15)         | 36 (7)                  | <0.001    |
| Pneumonia without empyema| 149 (68)        | 331 (63)                |           |
| Others†                  | 38 (17)         | 158 (30)                |           |
| Shock at presentation    | 15 (7)          | 107 (20)                | <0.001    |
| 30-day mortality         | 11 (5)          | 107 (20)                | <0.001    |
| Antibiotic Resistance‡   |                 |                         |           |
| Penicillin               |                 |                         |           |
| Non-meningeal (MIC≥4 μg/mL) | 4 (2) | 12 (2) | 0.688 |
| Meningeal (MIC≥0.12 μg/mL) | 36 (16) | 180 (34) | <0.001 |
| Cefotaxime/Ceftriaxone    |                 |                         |           |
| Non-meningeal (MIC≥2 μg/mL) | 4 (2) | 10 (2) | 0.937 |
| Meningeal (MIC≥1 μg/mL)  | 17 (8)          | 81 (15)                 | 0.011     |
| Erythromycin (MIC≥0.5 μg/mL) | 33 (15) | 124 (24) | 0.009 |

Unless otherwise indicated, data are reported as number (percentage). MIC denotes minimum inhibitory concentration.

*Co-morbidities (some patients had more than one): HIV infection (n = 159), malignant disease (n = 143), chronic liver disease (n = 131), immunosuppressive therapy (n = 128), diabetes (n = 92), chronic pulmonary disease (n = 82), cardiovascular diseases (n = 45), transplant recipients (n = 29), chronic rheumatic disease or vasculitis (n = 20), asplenia (n = 19), end stage renal failure (n = 17), cerebrovascular diseases/degenerative brain diseases (n = 7).

†Other clinical syndromes (healthy (n) vs. co-morbidities (n)): primary bacteremia (3 vs. 42), meningitis (27 vs. 37), spontaneous bacterial peritonitis (0 vs. 50), abdominal/biliary tract (2 vs. 11), soft tissue infections (0 vs. 7), endocarditis (3 vs. 0), osteoarticular (2 vs. 5); otitis/sinusitis (1 vs. 6).

‡According to the new Clinical Laboratory Standard Institute breakpoints. Resistance to other antibiotics (healthy vs. co-morbidities): tetracycline (12% vs. 26%); co-trimoxazole (20% vs. 41%) and ciprofloxacin (0.5% vs. 1%).

doi:10.1371/journal.pone.0042595.t001
The vaccine serotype coverage (2006–2010) was higher in healthy adults than in patients with co-morbidities for PCV13 (82% vs. 56%, P<0.001) and for PCV10 (63% vs. 35%, P<0.001), while it was lower for PCV7 (14% vs. 25%, P = 0.022).

Of 79 serotype 1 isolates, 72 were genotyped, which were included into two genotypes related to ST304 (N = 15, Sweden1-ST304) and ST306 (N = 57, Sweden1-ST306). There was an emergence of ST306 during the study period: 43% (6/18 isolates) in 1996–2000, 91% (21/23) in 2001–2005 and 86% (30/35) in 2006–2010 (P = 0.001). Of 49 serotype 7F isolates, 48 were genotyped and shared a common genotype related to ST191 (Netherlands7F-ST191 clone). Of 25 serotype 5 isolates, 22 were genotyped and shared a common PFGE type related to Columbia5-ST289 clone and associated with two STs (ST289 and ST1223).

Multivariate analyses

Tables 1 and 2 show the clinical characteristics of IPD and serotypes. In a multiple logistic regression model, those variables independently associated with healthy adults (compared to patients with co-morbidities) were: younger age (<49 yrs) [OR = 1.85, 95%CI 1.29–2.65, P = 0.001], female sex [OR = 2.56, 95%CI 1.76–3.72, P<0.001], presentation with pneumonia plus empyema [OR = 2.14, 95%CI 1.19–3.85, P = 0.010], serotype 1 [OR = 6.86, 95%CI 3.99–11.81, P<0.001], serotype 5 [OR = 5.53, 95%CI 2.33–13.11, P<0.001], and serotype 7F [OR = 3.82, 95%CI 2.04–7.13, P<0.001].

Mortality

As expected, the healthy adults with IPD had a lower mortality rate than patients with co-morbidities (Table 1), and this persisted significantly lower after adjustment for age, gender, clinical presentation and serotypes [adjusted OR = 0.31, 95%CI 0.16–0.62, P = 0.001].

Of note, no deaths occurred among the 79 patients with serotype 1 IPD. However, 12% (6/49) of patients with serotype 7F and 8% (2/25) of patients with serotype 5, died.
Table 3 shows the 11 healthy adults with IPD who died. Early death occurred in 4 patients (2 with fulminant sepsis and 2 with meningitis). Two patients with endocarditis, without underlying cardiac disease, had a history of alcohol abuse and one of them died because of complications of cardiac surgery and the other due to a nosocomial infection. A 19-year old boy who presented with progressive bilateral pneumonia caused by serotype 3 died. The remaining 4 patients had extensive bacteremic pneumonia caused by serotypes 14 or 7F. In all cases the pneumococcal isolates were susceptible to the antibiotics administered.

Pneumonia and empyema

Among 549 patients with pneumonia, 69 (13%) had associated empyema with isolation of \textit{S. pneumoniae} in pleural fluid ("empyema group"), and 480 (87%) had pneumonia without empyema ("pneumonia group") (Table 4).

Empyema occurred more frequently in healthy adults and was often associated with serotype 1, particularly the clonal-type Sweden\textsuperscript{1}-ST306 (15 of 17 cases).

Discussion

In our study, about one third of adults (aged 18–64 years) with IPD were healthy, and we observed an increase in IPD caused by non-PCV7 serotypes, particularly the serotypes 1, 7F and 5. Of special concern has been the spread of some specific clonal-types, such as Sweden\textsuperscript{1}-ST306 of serotype 1 that was strongly associated with empyema.

Our findings are consistent with some reports considering serotypes 1, 5 and 7F as primary pathogens with a high invasive disease potential, because they often cause IPD in children but are associated with a brief duration of colonization and are rarely found in the nasopharynx. [22–25]. The serotype 1 clone (Sweden\textsuperscript{1}-ST306) seen in our study was first identified in Sweden in 1990’s with a subsequent spread to other European countries [24,26–31].

Smokers and alcohol abusers are at greater risk for IPD [5,8]. Indeed, our healthy adults with IPD were frequently smokers or alcohol abusers; and we decided not to exclude them from the healthy adults group in order to identify factors suitable for future vaccination strategies. Thus, our results suggest that avoiding smoking and alcohol abuse and reinforcing the pneumococcal vaccination (CDC recommendations) for active smokers and alcohol abusers [9] may reduce the IPD rates in adults. These data support the initiative of Joint Commission’s tobacco-cessation interventions in patients attending health care visits [32].

The increased proportion of women among our healthy adults with IPD may reflect that healthy women have often contact with

![Figure 2. Serotype distribution among 295 pneumococcal isolates causing adult IPD in more recent years (period 2006–2010). doi:10.1371/journal.pone.0042595.g002](image-url)
Table 2. Serotype distribution among 745 invasive pneumococcal isolates from adults (healthy vs. co-morbidities).

| Serogroups /serotypes | Healthy N = 216* | Co-morbidities N = 513* | P value |
|------------------------|-----------------|------------------------|--------|
|                        | n° strains (%)  |                        |        |
| 1                      | 55 (25)         | 24 (5)                 | <0.001 |
| 3                      | 21 (10)         | 33 (6)                 | 0.121  |
| 4                      | 11 (5)          | 25 (5)                 | 0.901  |
| 5                      | 15 (7)          | 10 (2)                 | 0.001  |
| 6A                     | 5 (2)           | 12 (2)                 | 0.984  |
| 6B                     | 2 (1)           | 11 (2)                 | 0.364  |
| 6C                     | 1 (0.5)         | 8 (2)                  | 0.458  |
| 7F                     | 27 (13)         | 22 (4)                 | <0.001 |
| 8                      | 7 (3)           | 20 (4)                 | 0.668  |
| 9N                     | 0               | 11 (2)                 | -      |
| 9V                     | 7 (3)           | 30 (6)                 | 0.143  |
| 11A                    | 4 (2)           | 14 (3)                 | 0.607  |
| 12                     | 7 (3)           | 17 (3)                 | 0.960  |
| 14                     | 12 (6)          | 37 (7)                 | 0.415  |
| 18C                    | 3 (1)           | 14 (3)                 | 0.420  |
| 19A                    | 12 (6)          | 37 (7)                 | 0.415  |
| 19F                    | 3 (1)           | 30 (6)                 | 0.006  |
| 23A                    | 0               | 11 (2)                 | -      |
| 23F                    | 2 (1)           | 27 (5)                 | 0.006  |
| Others\(^1\)           | 22 (10)         | 120 (23)               | <0.001 |

*A total of 745 IPD episodes. Out of 220 IPD in healthy adults, 216 (98%) were serotyped. Out of 525 IPD in patients with co-morbidities, 513 (98%) were serotyped.

\(^1\) Others (healthy (n) vs. co-morbidities (n)): 10A (2 vs. 10), 13 (0 vs. 3), 15A (3 vs. 9), 15B (0 vs. 9), 15C (0 vs. 3), 15F (0 vs. 4), 16F (0 vs. 5), 17 (0 vs. 5), 18A (0 vs. 1), 18B (0 vs. 1), 20 (0 vs. 10), 21 (0 vs. 1), 22F (5 vs. 8), 23B (2 vs. 2), 24F (2 vs. 8), 25 (2 vs. 1), 28 (0 vs. 2), 29 (0 vs. 2), 31 (0 vs. 5), 32 (0 vs. 1), 33 (3 vs. 4), 34 (0 vs. 1), 35 (1 vs. 13), 37 (0 vs. 1), 38 (0 vs. 2), 48 (0 vs. 1), non-typable (2 vs. 2).

Pneumococcal Disease in Healthy Adults

capsular polysaccharide structure, surface proteins properties or the pneumolysin might explain some differences in the clinical presentation [25,35].

Also, it is unknown why serotype 1 is more prevalent in older children and healthy adults than in patients with co-morbidities. We can speculate that patients with co-morbidities, who often undergo antibiotic pressure and may have local and systemic immunodeficiencies, are more predisposed to be colonized/infected with multi-resistant serotypes -with low invasive disease potential- such as 19F and 23F, and because of a phenomenon of "competition among serotypes in the nasopharyngeal niche" they could be less predisposed to acquire other serotypes such as serotype 1. On the contrary, healthy adults who are not usually nasopharyngeal carriers could be more predisposed to be infected with invasive serotypes, which act as primary pathogens, such as serotype 1.

Some reports have shown a low mortality of serotype 1 IPD [36,37]. Interestingly, none of our 79 patients with IPD caused by serotype 1 died, which may be related to host's characteristic (e.g., healthy people) or differences in pneumococcal-dependent factors (e.g., capacity to generate a host inflammatory response) [23]. It is well known the widely geographical variation of serotype 1, which is quite prevalent in several European countries but less common in USA and Canada [25]. Also, several epidemics of serotype 1 IPD have been reported in South American, Asian and African countries [25,30]. It is possible that genetic and environmental factors as well as clonal-type dissemination may explain some of these differences. For example, cases of serotype 1 IPD reported in USA were often caused by a different clonal-type, the ST227 [39].

We also found a high prevalence of serotypes 7F and 5 among healthy adults. The characteristics of IPD caused by these serotypes were quite similar to those of serotype 1, except that were less strongly associated with empyema and some of them died. Serotype 3 was also prevalent in healthy adults as well as in patients with co-morbidities (Table 2).

We found that the serotype coverage of the recently introduced PCV13 was higher in healthy adults than in patients with co-morbidities, which reflects a different serotype distribution. We do not know if in areas with increased prevalence of serotype 1 (which affects more frequently children and healthy adults), the use of PCV13 for children <2 yrs will be associated with a decline of IPD in healthy adults (by herd protection). Recent studies have evaluated the cost-effectiveness of PCV13 compared to PPV23 in adult vaccination, and suggest an advantage of the PCV13 with the assumption that it would be effective against non-bacteremic pneumococcal pneumonia [40]. Although our study refers to a large cohort of patients with IPD, it may have some limitations: 1) the study was performed in Barcelona and these results may not be entirely extrapolated to other geographical areas; 2) our study did not show specific incidence rates of IPD in healthy people and in patients with co-morbidities since we do not know these denominators; and 3) we could not investigate other possible risk factors for IPD such as viral co-infections, nor the close contact with young children.

In conclusion, our study shows that IPD often occurs in healthy adults, particularly smokers and alcohol abusers, and frequently presents with pneumonia and empyema associated with virulent clones of non-PCV7 serotypes. Thus, implementing tobacco and alcohol abuse-cessation measures and a proper pneumococcal vaccination, which may include a broader spectrum conjugate vaccines such as PCV13, in active smoker and alcohol abusers may diminish the burden of IPD in adults.
**Table 3.** Summary of the 11 healthy adults with invasive pneumococcal disease who died.

| Patient | Sex/Age (yr) | Alcohol abuse | Current smoking | Clinical syndrome | Source of isolate | Shock at presentation | Antibiotic therapy | Days to death | Serotype |
|---------|--------------|---------------|-----------------|-------------------|-------------------|----------------------|-------------------|--------------|---------|
| 1       | M/52         | Yes           | Yes             | Endocarditis/ Meningitis | blood           | No                   | CTX               | 29           | 10A     |
| 2       | M/42         | Yes           | Yes             | Endocarditis      | blood           | Yes                  | CRO               | 16           | 4       |
| 3       | M/19         | No            | Yes             | Pneumonia         | blood           | Yes                  | CRO+LEVO          | 30           | 14      |
| 4       | F/53         | No            | No              | Pneumonia         | blood           | Yes                  | CRO               | 29           | 7F      |
| 5       | F/58         | No            | No              | Pneumonia         | blood           | Yes                  | CRO               | 10           | 14      |
| 6       | M/49         | Yes           | No              | Pneumonia         | blood           | No                   | LEVO              | 1            | 6A      |
| 7       | M/36         | No            | No              | Sepsis            | blood           | Yes                  | CRO               | 1            | ND      |
| 8       | F/40         | No            | Yes             | Pneumonia         | blood           | Yes                  | CRO               | 12           | 7F      |
| 9       | M/37         | No            | No              | Meningitis        | Blood/CSF      | No                   | VAN+RIFA          | 4            | 3       |
| 10      | M/39         | No            | Yes             | Sepsis            | blood           | Yes                  | CTX               | 1            | ND      |
| 11      | M/59         | No            | Yes             | Meningitis        | Blood/CSF      | Yes                  | CTX               | 3            | 3       |

**Abbreviations:** M, male; F, female; CTX, cefotaxime; CRO, ceftriaxone; LEVO, levofloxacin; VAN, vancomycin; RIFA, rifampin; ND, not done.

**Table 4.** Pneumococcal pneumonia in 549 adults: A comparison between patients with pneumonia and empyema (Empyema group) and those with pneumonia without empyema (Pneumonia group).

|                          | Empyema group N = 69 | Pneumonia group N = 480 | P  |
|--------------------------|----------------------|------------------------|----|
| Age, mean+/− 5D, years   | 46.83 (+/− 12.83)    | 46.74 (+/− 12.23)      | 0.959 |
| 18–49 yrs                | 33 (48)              | 261 (54)               | 0.308 |
| 50–64 yrs                | 36 (52)              | 219 (46)               | 0.998 |
| Sex                      |                      |                        |    |
| Female                   | 21 (30)              | 146 (30)               | 0.006 |
| Male                     | 48 (70)              | 334 (70)               | 0.986 |
| Underlying diseases      |                      |                        |    |
| Healthy                  | 33 (48)              | 149 (31)               | 0.448 |
| Co-morbidities*          | 36 (52)              | 331 (69)               | 0.968 |
| Alcohol abuse            | 13 (19)              | 115 (24)               | 0.027 |
| Current smoking          | 40 (58)              | 301 (63)               | 0.060 |
| Multilobar pneumonia     | 20 (29)              | 145 (30)               | 0.198 |
| Respiratory failure      | 33 (48)              | 220 (46)               | 0.032 |
| Shock at presentation    | 7 (10)               | 88 (18)                | 0.013 |
| 30-day mortality         | 6 (9)                | 71 (15)                | 0.003 |
| Serotypes*               |                      |                        |    |
| Serotype 1               | 17 (25)              | 56 (12)                | 0.003 |
| Serotype 3               | 8 (12)               | 35 (7)                 | 0.162 |
| Serotype 7F              | 4 (6)                | 41 (9)                 | 0.320 |
| Others                   | 39 (57)              | 340 (72)               | 0.013 |

Unless otherwise indicated, data are reported as number (percentage).

*Co-morbidities in the empyema group (n) vs. pneumonia group (n) (some patients had more than one): HIV infection (9 vs. 116), malignant disease (15 vs. 85), chronic liver disease (4 vs. 55), immunosuppressive therapy (11 vs. 78), diabetes (5 vs. 57), chronic pulmonary disease (7 vs. 62), cardiovascular disease (2 vs. 33), chronic rheumatic disease or vasculitis (0 vs. 15), asplenia (1 vs. 3), end stage renal failure (3 vs. 12), transplant recipients (1 vs. 17), cerebrovascular or degenerative brain disease (1 vs. 5).

The most common serotypes in patients of empyema group (68/69 serotyped) were: serotype 1 (25%), 3 (12%), 7F (6%), 5 (4%), 19A (4%), 19F (4%), 23F (4%), 4 (3%), 6A (3%), 6B (3%), 8 (3%), 9V (3%), 18C (3%), 23A (3%) and 22 (3%).

The most common serotypes in patients of pneumonia group (472/480 serotyped) were: serotype 1 (12%), 7F (9%), 14 (8%), 19A (8%), 3 (7%), 4 (6%), 9V (5%), 5 (5%), 8 (5%), 12F (4%), 23F (3%), 11A (3%), 18C (3%) and 19F (2%).

doi:10.1371/journal.pone.0042595.t003

doi:10.1371/journal.pone.0042595.t004
Acknowledgments

This study was presented in part (Abstract: L1-1035) to the 50th-Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12–15, 2010. Boston, USA.

Author Contributions

Conceived and designed the experiments: IG RP. Performed the experiments: IG CA LG DR AD JL RP. Analyzed the data: IG CA JL RP. Contributed reagents/materials/analysis tools: IG CA LC DR AD JL RP. Wrote the paper: IG RP. Critical revision of the manuscript for important intellectual content: IG CA LC DR AD JL RP. Statistical analysis: IG RP. Obtained funding: JL RP. Administrative, technical, or material support: IG CA LC DR AD JL RP. Study supervision: IG RP.

References

1. Bogart D, De Groot R, Hermann PW (2004) Staphylococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4: 144–154.

2. De Lancastre H, Tomasz A (2002) From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Staphylococcus pneumoniae. J Antimicrob Chemother 50 Suppl 52: 73–81.

3. Handshon WP, Finkel DR, Klagman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5: 83–93.

4. Mushum DM, Alexandra I, Gravius EA, Vanhee Y, Ela A, et al. (2000) Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine 79: 210–221.

5. Kyaw MH, Rose CE, Jr, Fry AM, Singleton JA, Moore Z, et al. (2005) The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 192: 377–386.

6. Klemets P, Lyttkainen O, Rontu P, Ollgren J, Nuorti JP (2008) Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis 8: 96.

7. Marrie TJ, Tyrell GJ, Gagg S, Vanderkooi OG (2011) Factors predicting mortality in invasive pneumococcal disease in adults in Alberta. Medicine 90: 171–179.

8. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGee A, et al. (2000) Cocaine smoking and invasive pneumococcal disease. N Engl J Med 342: 681–689.

9. Advisory Committee on Immunization Practices (2012) Recommended Adult Immunization Schedule, United States. Ann Intern Med 156:211–10.

10. Huss A, Scott P, Stuck AE, Trotter C, Egger M (2009) Efficacy of pneumococcal conjugate vaccination in adults: a meta-analysis. CMAJ 180: 60–66. Erratum in: CMAJ 2009;180:1038.

11. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737–1746.

12. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennet NM, et al. (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360: 244–256.

13. Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962–1973.

14. Miller E, Andrews NJ, Waigh PA, Slack MP, George RC, et al. (2011) Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11:769–768.

15. Pallares R, Lañares J, Vadillo M, Cabellos C, Manresa F, et al. (1995) Resistance to penicillin and cephalosporin and mortality from severe pneumococcal disease. J Antimicrob Chemother 50 Suppl S2: 75–81.

16. Musher DM, Alexandraki I, Graviss EA, Yanbeiy N, Eid A, et al. (2000) Temporal and geographic stability of the serogroup-specific invasive disease potential of Staphylococcus pneumoniae in children. J Infect Dis 190: 1203–1211.

17. Sjöstrom K, Spindler C, Orqvist A, Kalin M, Sandgren A, et al. (2006) Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 42: 451–459.

18. Burges J, Lajane M, Falco Y, Nández A, Puig M, et al. (2011) The spectrum of pneumococcal empyema in adults in the early 21st century. Clin Infect Dis 53: 254–261.

19. Ritchie ND, Mitchell TJ, Evans TJ (2012) What is different about serotype 1 pneumococci? Future Microbiol 7: 33–46.

20. Henríquez Normark B, Kalin M, Ortyści A, Akerlund T, Liljestrand BO, et al. (2001) Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J Infect Dis 184: 861–869.

21. Esteve C, Selva L, de Sevilla MF, Garcia-Garcia JJ, Pallares R, et al. (2011) Staphylococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989–2008). Clin Microbiol Infect 17: 1441–1444.

22. Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, Del Castello F, et al. (2011) Laboratory-based, 2-year surveillance of pediatric parapneumonic pneumococcal empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in Madrid. Pediatr Infect Dis J 30: 471–474.

23. Brueggemann AB, Spratt BG (2005) Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates. J Clin Microbiol 41:4966–4970.

24. Marimon JM, Echevergou M, Alonso M, Zubizarreta M, Perez-Trailero E (2009) Clonal structure and 21-year evolution of Streptococcus pneumoniae serotype 1 isolates in Northern Spain. Clin Microbiol Infect 15: 875–877.

25. Sá-Leão R, Pinto F, Aguier S, Nunes S, Gairó PC, et al. (2011) Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. J Clin Microbiol 49:13–15.

26. Fiore MC, Gooslon E, Schroeder SA (2012) The Joint Commission’s New Tobacco-Cessation Measures — Will Hospitals Do the Right Thing?. New Engl J Med 366:1172–4.

27. Bernstein JK, Klagman KP, Jones RN (2009) Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 49: 1596–1600.

28. Ferrol A, Aguilar I, Vicioso MD, Gimenez MJ, Robledo O, et al. (2010) Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008. Antimicrob Agents Chemother 54: 5307–5310.

29. Muñoz R, Lopez R, De Frutos M, Garcia E (1999) First molecular characterization of a uridine diphosphate galacturonic-4-epimerase: an enzyme required for capsular biosynthesis in Streptococcus pneumoniae type 1. Mol Microbiol 31:703–713.

30. Harboe ZB, Thomsen RW, Riis A, Valentin-Brath P, Christensen JF, et al. (2009) Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 6: e1000881.

31. Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klagman KP, et al. (2010) Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 51: 692–699.

32. Gesnzer BD, Mueller JE, Yaro S (2010) African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. BMC Infect Dis 10:22.

33. Beall B, McElhenny MC, Gertz RE Jr, Wedel S, Boyd JD, et al. (2006) Active Bacterial Core Surveillance Team. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44: 999–1017.

34. Smith KJ, Wateska AR, Nowalk MP, Raymond M, Nuorti JP, et al. (2012) Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 307: 804–812.

Pneumococcal Disease in Healthy Adults